Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

BMC Cancer

Table 5 Evaluation of the predictive value of clinical factors and biomarkers for the treatment effect in terms of PFS

Parameters	p-value of the interaction term treatment arm x factor^a
Clinical characteristics
Location	0.26
Medical history	0.29
Baseline biomarkers
Human FGF (pg/mL)	0.28
PlGF (pg/mL)	0.57
SCF sR/c-kit (ng/mL)	0.27
sE-Selectin (ng/mL)	0.48
TSP-1 (μg/mL)	0.06
VEGF (ng/mL)	0.82
VEGF-C (ng/mL)	0.77
Variation (D8-D1)
Human FGF (pg/mL)	0.60
PlGF (pg/mL)	0.67
SCF sR/c-kit (ng/mL)	0.60
sE-Selectin (ng/mL)	0.62
TSP-1 (μg/mL)	0.28
VEGF (ng/mL)	0.45
VEGF-C (ng/mL)	0.93